Poon Christine A's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Oct 31, 2025
- Accession no.
- 0001189014-25-000005
- Filed
- Oct 31, 2025
- Trade date
- Oct 29-30, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 8 non-derivative transactions and 2 derivative transactions. Open-market sales total $4.25M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Poon Christine ACIK 0001189014 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 29, 2025 | Common Stock | MOption exerciseAcquired | +6,500 | $520.01 | +$3,380,065 | 8,852 | Direct | |
| Oct 29, 2025 | Common Stock | SSaleDisposed | −650 | $652.68F1 | −$424,242 | 8,202 | Direct | |
| Oct 29, 2025 | Common Stock | SSaleDisposed | −2,735 | $653.50F2 | −$1,787,322.5 | 5,467 | Direct | |
| Oct 29, 2025 | Common Stock | SSaleDisposed | −1,915 | $654.42F3 | −$1,253,214.3 | 3,552 | Direct | |
| Oct 29, 2025 | Common Stock | SSaleDisposed | −100 | $655.10F4 | −$65,510 | 3,452 | Direct | |
| Oct 29, 2025 | Common Stock | SSaleDisposed | −712 | $656.50F5 | −$467,428 | 2,740 | Direct | |
| Oct 29, 2025 | Common Stock | SSaleDisposed | −388 | $657.29F6 | −$255,028.52 | 2,352 | Direct | |
| Oct 30, 2025 | Common Stock | MOption exerciseAcquired | +2,712 | $520.01 | +$1,410,267.12 | 5,064 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 29, 2025 | Common Stock | MOption exerciseDisposed | −6,500 | $0.00 | $0 | 2,712 | Direct | |
| Oct 30, 2025 | Common Stock | MOption exerciseDisposed | −2,712 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents volume-weighted average price of sales of 650 shares of Company stock on October 29, 2025 at prices ranging from $652.31 to $652.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F2
Represents volume-weighted average price of sales of 2,735 shares of Company stock on October 29, 2025 at prices ranging from $653.05 to $653.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Represents volume-weighted average price of sales of 1,915 shares of Company stock on October 29, 2025 at prices ranging from $654.01 to $654.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
Represents volume-weighted average price of sales of 100 shares of Company stock on October 29, 2025 at prices ranging from $655.02 to $655.16. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
Represents volume-weighted average price of sales of 712 shares of Company stock on October 29, 2025 at prices ranging from $656.33 to $656.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F6
Represents volume-weighted average price of sales of 388 shares of Company stock on October 29, 2025 at prices ranging from $657.02 to $657.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
Referenced by the price of 1 transaction in Table I.